Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PXS-5505A by Syntara for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PXS-5505A is under clinical development by Syntara and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Data Insights
PXS-5505A by Syntara for Scar: Likelihood of Approval
PXS-5505A is under clinical development by Syntara and currently in Phase I for Scar. According to GlobalData, Phase I drugs...